RATIONALE: Avoidance of contexts directly associated with fearful experiences represents an adaptive behavioral survival strategy. Over-interpretation of contextual cues leading to generalized avoidance of situations that are only remotely similar to the original fear context represents a pathologic process that contributes to anxiety disorders. Orexin neuropeptides modulate anxiety-like behavioral and physiological responses. OBJECTIVE: The objective of this paper was to investigate the impact of pharmacological orexin receptor blockade on generalized avoidance behavior. METHODS: Rats received a single electric foot-shock in the dark side of a two-compartment shuttle box followed by situational context reminders. After shock, rats were treated chronically (3 weeks) with the orexin receptor antagonist almorexant or with the selective serotonin reuptake inhibitor sertraline, used as positive anxiolytic control. In week 3, avoidance behavior was measured under conditions of high (dark-light (DL)-box) and low (elevated plus maze (EPM)) similarity to the original shock context. Avoidance behavior was re-assessed 5 and 17 weeks after treatment termination. RESULTS: Avoidance in the DL box (contextual fear memory) remained unaffected by any treatment and lasted 20 weeks post-shock exposure. Avoidance in the EPM (neophobic fear generalization) was partially attenuated during treatment with almorexant and sertraline at week 3. Following 5 and 17 weeks of drug washout, avoidance in the EPM was significantly reduced in almorexant- but not in sertraline-treated rats. Almorexant also reduced persistent avoidance in the EPM upon treatment initiation 3 weeks after shock exposure. CONCLUSION: Chronic orexin receptor blockade in rats reduces both the development and persistence of generalized avoidance in situations with low similarity to the initial shock context.
RATIONALE: Avoidance of contexts directly associated with fearful experiences represents an adaptive behavioral survival strategy. Over-interpretation of contextual cues leading to generalized avoidance of situations that are only remotely similar to the original fear context represents a pathologic process that contributes to anxiety disorders. Orexin neuropeptides modulate anxiety-like behavioral and physiological responses. OBJECTIVE: The objective of this paper was to investigate the impact of pharmacological orexin receptor blockade on generalized avoidance behavior. METHODS:Rats received a single electric foot-shock in the dark side of a two-compartment shuttle box followed by situational context reminders. After shock, rats were treated chronically (3 weeks) with the orexin receptor antagonist almorexant or with the selective serotonin reuptake inhibitor sertraline, used as positive anxiolytic control. In week 3, avoidance behavior was measured under conditions of high (dark-light (DL)-box) and low (elevated plus maze (EPM)) similarity to the original shock context. Avoidance behavior was re-assessed 5 and 17 weeks after treatment termination. RESULTS: Avoidance in the DL box (contextual fear memory) remained unaffected by any treatment and lasted 20 weeks post-shock exposure. Avoidance in the EPM (neophobic fear generalization) was partially attenuated during treatment with almorexant and sertraline at week 3. Following 5 and 17 weeks of drug washout, avoidance in the EPM was significantly reduced in almorexant- but not in sertraline-treated rats. Almorexant also reduced persistent avoidance in the EPM upon treatment initiation 3 weeks after shock exposure. CONCLUSION: Chronic orexin receptor blockade in rats reduces both the development and persistence of generalized avoidance in situations with low similarity to the initial shock context.
Authors: Valerie G Olson; Hannah R Rockett; Rebecca K Reh; Van A Redila; Phuong M Tran; Heli A Venkov; Mia C Defino; Chris Hague; Elaine R Peskind; Patricia Szot; Murray A Raskind Journal: Biol Psychiatry Date: 2011-01-20 Impact factor: 13.382
Authors: Christopher J Winrow; Anthony L Gotter; Christopher D Cox; Scott M Doran; Pamela L Tannenbaum; Michael J Breslin; Susan L Garson; Steven V Fox; Charles M Harrell; Joanne Stevens; Duane R Reiss; Donghui Cui; Paul J Coleman; John J Renger Journal: J Neurogenet Date: 2011-04-08 Impact factor: 1.250
Authors: Dean Kirson; Michael Q Steinman; Sarah A Wolfe; Samantha R Spierling Bagsic; Michal Bajo; Suhas Sureshchandra; Christopher S Oleata; Ilhem Messaoudi; Eric P Zorrilla; Marisa Roberto Journal: J Neurosci Res Date: 2021-10-22 Impact factor: 4.433
Authors: Vijayakumar Mavanji; Tammy A Butterick; Cayla M Duffy; Joshua P Nixon; Charles J Billington; Catherine M Kotz Journal: Neurobiol Learn Mem Date: 2017-10-28 Impact factor: 2.877
Authors: D Verma; B Hörmer; K Bellmann-Sickert; V Thieme; A G Beck-Sickinger; H Herzog; G Sperk; R O Tasan Journal: Br J Pharmacol Date: 2016-05-19 Impact factor: 8.739
Authors: Le Shi; Wenhao Chen; Jiahui Deng; Sijing Chen; Ying Han; Muhammad Z Khan; Jiajia Liu; Jianyu Que; Yanping Bao; Lin Lu; Jie Shi Journal: Front Neurosci Date: 2018-05-03 Impact factor: 4.677
Authors: Michael Q Steinman; Dean Kirson; Eric P Zorrilla; Marisa Roberto; Sarah A Wolfe; Sophia Khom; Shannon R D'Ambrosio; Samantha R Spierling Bagsic; Michal Bajo; Roman Vlkolinský; Noah K Hoang; Anshita Singhal; Suhas Sureshchandra; Christopher S Oleata; Ilhem Messaoudi Journal: Mol Psychiatry Date: 2020-10-21 Impact factor: 15.992